His PSA exhibited a substantial reduction (4.91 ng/mL; Figure 2), improvements in renal function were observed (blood urea nitrogen 57 mg/dL, creatinine 1.7 mg/dL, creatinine clearance 37.06 mL/min, stage 3B CKD), his electrolyte levels were normal, and the treatment was well tolerated without considerable side effects. The gene discussed is KLK3; the disease is chronic kidney disease.